During the corresponding time, Citius Pharmaceuticals Inc sequentially revenue fell by -10.41 %. While revenue at the Citius Pharmaceuticals Inc 's corporate clients
Citius Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
Citius Oncology targets pharmaceutical companies with extensive sales forces and marketing capabilities as potential partners for its non-specialty product candidates. For LYMPHIR, the company has contracted a large third-party commercial sales and marketing organization to establish a dedicated field force and develop marketing programs directed at physicians and patients. The commercial focus includes prescribing hematologists, oncologists, dermatologist-oncologists, key opinion leaders, and advocacy groups involved in cutaneous T-cell lymphoma (CTCL) treatment. Distribution agreements are in place with Cardinal Health, Cencora, and McKesson Corporation. EVERSANA provides integrated pre- and post-launch services such as medical information, pharmacovigilance, and revenue cycle management. Citius Oncology is also working with regional distribution partners for Named Patient Programs in Europe, South America, and the Middle East, including an exclusive distribution agreement with Integris Pharma S.A. covering multiple European countries. LYMPHIR is included in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation and has received a unique HCPCS J-code (J9161) from CMS to support coverage and reimbursement.
Citius Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
Citius Oncology targets pharmaceutical companies with extensive sales forces and marketing capabilities as potential partners for its non-specialty product candidates. For LYMPHIR, the company has contracted a large third-party commercial sales and marketing organization to establish a dedicated field force and develop marketing programs directed at physicians and patients. The commercial focus includes prescribing hematologists, oncologists, dermatologist-oncologists, key opinion leaders, and advocacy groups involved in cutaneous T-cell lymphoma (CTCL) treatment. Distribution agreements are in place with Cardinal Health, Cencora, and McKesson Corporation. EVERSANA provides integrated pre- and post-launch services such as medical information, pharmacovigilance, and revenue cycle management. Citius Oncology is also working with regional distribution partners for Named Patient Programs in Europe, South America, and the Middle East, including an exclusive distribution agreement with Integris Pharma S.A. covering multiple European countries. LYMPHIR is included in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation and has received a unique HCPCS J-code (J9161) from CMS to support coverage and reimbursement.
Sources:
Citius Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Citius Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Citius Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
575.03 %